📣 VC round data is live. Check it out!

Edwards Lifesciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Edwards Lifesciences and similar public comparables like Siemens Healthineers, IDEXX Laboratories, Waters, Alcon and more.

Edwards Lifesciences Overview

About Edwards Lifesciences

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.


Founded

1999

HQ

United States

Employees

16.0K

Financials (LTM)

Revenue: $6B
EBITDA: $2B

EV

$45B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Edwards Lifesciences Financials

Edwards Lifesciences reported last 12-month revenue of $6B and EBITDA of $2B.

In the same LTM period, Edwards Lifesciences generated $5B in gross profit, $2B in EBITDA, and $2B in net income.

Revenue (LTM)


Edwards Lifesciences P&L

In the most recent fiscal year, Edwards Lifesciences reported revenue of $6B and EBITDA of $2B.

Edwards Lifesciences is profitable as of last fiscal year, with gross margin of 78%, EBITDA margin of 30%, and net margin of 25%.

See analyst estimates for Edwards Lifesciences
LTMLast FY202320242025202620272028
Revenue$6B$6B$6B$5B$6B
Gross Profit$5B$5B$5B$4B$5B
Gross Margin78%78%77%79%78%
EBITDA$2B$2B$2B$2B$1B
EBITDA Margin31%30%29%32%24%
EBIT Margin28%27%29%27%27%
Net Profit$2B$1B$1B$4B$1B
Net Margin25%25%23%77%18%

Financial data powered by Morningstar, Inc.

Edwards Lifesciences Stock Performance

Edwards Lifesciences has current market cap of $48B, and enterprise value of $45B.

Market Cap Evolution


Edwards Lifesciences' stock price is $83.20.

Edwards Lifesciences share price decreased by 0.4% in the last 30 days, and increased by 6.4% in the last year.

Edwards Lifesciences has an EPS (earnings per share) of $2.60.

See more trading valuation data for Edwards Lifesciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$45B$48B0.3%-0.4%-3.8%6.4%$2.60

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Edwards Lifesciences Valuation Multiples

Edwards Lifesciences trades at 7.1x EV/Revenue multiple, and 23.2x EV/EBITDA.

See NTM and 2027E valuation multiples for Edwards Lifesciences

EV / Revenue (LTM)


Edwards Lifesciences Financial Valuation Multiples

As of May 22, 2026, Edwards Lifesciences has market cap of $48B and EV of $45B.

Edwards Lifesciences has a P/E ratio of 30.1x.

LTMLast FY202320242025202620272028
EV/Revenue7.1x7.4x7.5x8.3x7.4x
EV/EBITDA23.2x24.8x25.5x26.1x31.0x
EV/EBIT25.5x27.3x26.0x30.4x27.5x
EV/Gross Profit9.1x9.5x9.7x10.4x9.5x
P/E30.1x32.0x34.2x11.5x44.6x
EV/FCF36.7x33.7x71.4x172.9x33.7x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Edwards Lifesciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Edwards Lifesciences Margins & Growth Rates

Edwards Lifesciences grew revenue by 11% and EBITDA by 17% in the last fiscal year.

In the most recent fiscal year, Edwards Lifesciences reported gross margin of 78%, EBITDA margin of 30%, and net margin of 25%.

See estimated margins and future growth rates for Edwards Lifesciences

Edwards Lifesciences Margins

Last FY202420252026202720282029
Gross Margin78%79%78%78%
EBITDA Margin30%32%24%31%
EBIT Margin27%27%27%29%
Net Margin25%77%18%26%
FCF Margin22%5%22%20%

Edwards Lifesciences Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth11%(9%)12%11%
Gross Profit Growth12%(7%)10%12%
EBITDA Growth17%(2%)(16%)46%
EBIT Growth19%(14%)11%20%
Net Profit Growth16%198%(74%)62%
FCF Growth2%(59%)414%2%

Data powered by FactSet, Inc. and Morningstar, Inc.

Edwards Lifesciences Operational KPIs

Edwards Lifesciences' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Edwards Lifesciences' Rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Edwards Lifesciences' Rule of X is 60% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Edwards Lifesciences
LTMLast FY202320242025202620272028
Rule of 4041%43%
Bessemer Rule of X57%60%
Revenue per Employee$0.4M
Opex per Employee$0.2M
R&D Expenses to Revenue17%18%18%19%18%
Opex to Revenue51%48%52%51%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Edwards Lifesciences Competitors

Edwards Lifesciences competitors include Siemens Healthineers, IDEXX Laboratories, Waters, Alcon, Agilent, ResMed, GE HealthCare, Mindray, Boston Scientific and Medtronic.

Most Edwards Lifesciences public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Siemens Healthineers1.6x1.6x7.8x7.9x
IDEXX Laboratories10.3x10.0x29.5x28.2x
Waters12.2x8.7x34.1x25.6x
Alcon3.5x3.5x13.5x13.5x
Agilent4.9x4.8x17.0x16.3x
ResMed5.8x5.3x15.5x13.7x
GE HealthCare1.8x1.8x9.9x10.1x
Mindray5.2x5.1x15.3x15.6x

This data is available for Pro users. Sign up to see all Edwards Lifesciences competitors and their valuation data.

Start Free Trial

Edwards Lifesciences M&A Activity

Edwards Lifesciences has acquired 11 companies to date.

Last acquisition by Edwards Lifesciences was on September 4th 2025. Edwards Lifesciences acquired Vectorious Medical Technologies for $497M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Edwards Lifesciences

Vectorious Medical Technologies
JC Medical
Endotronix
JenaValve Technology
Description
Vectorious Medical Technologies is a developer of implantable sensors for heart failure management. Its V-LAP device deploys a battery-free microcomputer inside the heart to measure left atrial pressure continuously, outperforming traditional metrics like pulmonary capillary wedge pressure. The wireless implant transmits data to physicians for remote monitoring, aiding early intervention. Tel Aviv-based, the company completed first-in-human trials in 2018 and enrolled over 100 patients in European studies across Italy, Germany, the UK, and Israel by 2020. Vectorious secured CE Mark approval in 2023 and initiated US pivotal trials under FDA Breakthrough Device Designation.
JC Medical is a Suzhou-headquartered medtech company developing transcatheter heart valve systems for aortic regurgitation and mitral replacement. Its J-Valve platform features a low-profile delivery system and self-expanding nitinol frame, approved in China since 2021 with over 1,000 implants performed. JC Medical conducts global clinical trials in Europe and the US, partnering with Edwards Lifesciences for distribution. Founded in 2018, the firm operates R&D centers in Shanghai and Boston.
Endotronix is a Lisle, Illinois-headquartered developer of implantable wireless sensors for heart failure management. The company produces the Cordella pulmonary artery pressure sensor paired with a cloud-based patient management platform that tracks hemodynamic data to enable early intervention. Clinicians access real-time vital signs through the system, which supports remote monitoring and reduces hospital readmissions. Founded in 2007, Endotronix partners with healthcare providers to deploy its technology in outpatient settings across the United States.
JenaValve Technology is an Irvine-headquartered medical device company with facilities in Leeds and Munich that develops transcatheter heart valve systems. Its Trilogy Heart Valve received CE Mark in May 2021 for treating severe aortic regurgitation and stenosis in high-risk patients, holding FDA Breakthrough Device Designation for U.S. trials.
HQ CountryIsraelUnited StatesUnited StatesUnited States
HQ City
Tel Aviv
San Francisco, CA
Chicago, IL
Los Angeles, CA
Deal Date4 Sep 202519 Aug 202424 Jul 202424 Jul 2024
Valuation$497M$316M$675M$945M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Edwards Lifesciences acquisitions and their M&A valuation multiples.

Start Free Trial

Edwards Lifesciences Investment Activity

Edwards Lifesciences has invested in 6 companies to date.

Latest investment by Edwards Lifesciences was on August 19th 2024. Edwards Lifesciences invested in Genesis Medtech in their $25M Strategic investment round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by Edwards Lifesciences

Genesis Medtech
Caption Health
V-Wave
Endotronix
Description
Genesis Medtech is a medical device company that designs and manufactures cardiovascular implants, neurovascular devices, and orthopedic products. Headquartered in Shanghai, China, with operations in Singapore and the United States, the firm holds over 1,000 patents and supplies devices to hospitals across Asia, Europe, and North America.
Caption Health is a New York-headquartered developer of AI-powered ultrasound guidance software. The Caption AI platform assists clinicians in capturing diagnostic cardiac images using automated coaching on handheld devices. FDA-cleared for point-of-care use, it integrates with GE Healthcare systems and expands into primary care and telehealth settings. The company partners with health systems like Mount Sinai and plans clinical enhancements for broader cardiac assessments.
V-Wave is a Herzliya-headquartered medical device company with operations in the US, focused on cardiovascular implants for heart failure patients. The firm develops the Ventura interatrial shunt, a percutaneous device that reduces left atrial pressure to alleviate symptoms and hospitalizations. V-Wave conducts clinical trials in the US and Europe, demonstrating improved exercise tolerance in NYHA class III patients. Established in 2008, it has raised significant venture funding and secured FDA breakthrough designation for its shunt technology.
Endotronix is a Lisle, Illinois-headquartered developer of implantable wireless sensors for heart failure management. The company produces the Cordella pulmonary artery pressure sensor paired with a cloud-based patient management platform that tracks hemodynamic data to enable early intervention. Clinicians access real-time vital signs through the system, which supports remote monitoring and reduces hospital readmissions. Founded in 2007, Endotronix partners with healthcare providers to deploy its technology in outpatient settings across the United States.
HQ CountrySingaporeUnited StatesIsraelUnited States
HQ City
Singapore
Caesarea
Chicago, IL
Deal Date19 Aug 202415 Jul 202027 Apr 20185 Jul 2016
RoundStrategic investmentSeries BSeries CSeries C
Raised$25M$53M$70M$37M
InvestorsEdwards LifesciencesAtlantic Bridge; DCVC; Edwards Lifesciences; Gopher US Partners; Khosla Ventures; LDV Partners; New York Presbyterian Ventures; Nicolas Pinto; Olive Technology Ventures; Sachin GuptaAperture Venture Partners; BioStar Capital; BRM Capital; Deerfield; Edwards Lifesciences; Endeavour Vision; Israel Secondary Fund (ISF); Johnson & Johnson Robotics and Digital Solutions; Pontifax; Pura Vida Investments; Quark Venture; TriventuresAperture Venture Partners; Bioventures Investors; Edwards Lifesciences; Lumira Ventures; OSF Ventures; SV Health Investors
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Edwards Lifesciences investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Edwards Lifesciences

When was Edwards Lifesciences founded?Edwards Lifesciences was founded in 1999.
Where is Edwards Lifesciences headquartered?Edwards Lifesciences is headquartered in United States.
How many employees does Edwards Lifesciences have?As of today, Edwards Lifesciences has over 16K employees.
Who is the CEO of Edwards Lifesciences?Edwards Lifesciences' CEO is Bernard J. Zovighian.
Is Edwards Lifesciences publicly listed?Yes, Edwards Lifesciences is a public company listed on NYSE.
What is the stock symbol of Edwards Lifesciences?Edwards Lifesciences trades under EW ticker.
When did Edwards Lifesciences go public?Edwards Lifesciences went public in 2000.
Who are competitors of Edwards Lifesciences?Edwards Lifesciences main competitors include Siemens Healthineers, IDEXX Laboratories, Waters, Alcon, Agilent, ResMed, GE HealthCare, Mindray, Boston Scientific, Medtronic.
What is the current market cap of Edwards Lifesciences?Edwards Lifesciences' current market cap is $48B.
What is the current revenue of Edwards Lifesciences?Edwards Lifesciences' last 12 months revenue is $6B.
What is the current revenue growth of Edwards Lifesciences?Edwards Lifesciences revenue growth (NTM/LTM) is 11%.
What is the current EV/Revenue multiple of Edwards Lifesciences?Current revenue multiple of Edwards Lifesciences is 7.1x.
Is Edwards Lifesciences profitable?Yes, Edwards Lifesciences is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Edwards Lifesciences?Edwards Lifesciences' last 12 months EBITDA is $2B.
What is Edwards Lifesciences' EBITDA margin?Edwards Lifesciences' last 12 months EBITDA margin is 31%.
What is the current EV/EBITDA multiple of Edwards Lifesciences?Current EBITDA multiple of Edwards Lifesciences is 23.2x.
What is the current FCF of Edwards Lifesciences?Edwards Lifesciences' last 12 months FCF is $1B.
What is Edwards Lifesciences' FCF margin?Edwards Lifesciences' last 12 months FCF margin is 19%.
What is the current EV/FCF multiple of Edwards Lifesciences?Current FCF multiple of Edwards Lifesciences is 36.7x.
How many companies Edwards Lifesciences has acquired to date?As of May 2026, Edwards Lifesciences has acquired 11 companies.
What was the largest acquisition by Edwards Lifesciences?$945M acquisition of JenaValve Technology on 24th July 2024 was the largest M&A Edwards Lifesciences has done to date.
What companies Edwards Lifesciences acquired?Edwards Lifesciences acquired JenaValve Technology, Endotronix, Vectorious Medical Technologies, CardiAQ Valve Technologies, Valtech Cardio, JC Medical, Innovalve, Harpoon Medical, CAS Medical Systems, Corvia Medical, and 1 other company.
In how many companies Edwards Lifesciences has invested to date?As of May 2026, Edwards Lifesciences has invested in 6 companies.
What was the last Edwards Lifesciences investment?On 19th August 2024 Edwards Lifesciences invested in Genesis Medtech, participating in a $25M Strategic investment round.
In what companies Edwards Lifesciences invested in?Edwards Lifesciences invested in V-Wave, Caption Health, CardioKinetix, Endotronix, Genesis Medtech, and Middle Peak Medical.

See public comps similar to Edwards Lifesciences

Lists including Edwards Lifesciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial